Connect Biopharma Holdings Income Statement (2023-2025) | CNTB

Income Statement Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025
Revenue & cost
Revenue (Quarter) 24.12M1.22M0.70M0.05M0.02M
Operating items
Research & Development (Quarter) 8.66M5.35M9.01M6.24M6.63M8.77M11.11M11.28M
Selling, General & Administrative (Quarter) 3.97M5.12M6.06M4.08M4.81M4.70M6.58M4.24M
Operating Expenses (Quarter) 12.63M10.47M15.06M10.32M11.45M13.47M17.69M15.53M
Operating Income (Quarter) -12.63M13.65M-13.85M-9.62M-11.45M-13.42M-17.68M-15.53M
EBIT (Quarter) -12.63M13.65M-13.85M-9.62M-11.45M-13.42M-17.68M-15.53M
Non-operating items
Interest & Investment Income (Quarter) 1.25M1.22M1.14M0.85M0.72M0.62M0.55M0.38M
Other Non Operating Income (Quarter) 2.72M0.01M-0.11M-0.03M0.51M-0.04M-0.01M0.06M
Non Operating Income (Quarter) 2.72M1.23M1.03M-3.63M0.51M-0.04M-0.01M-1.82M
Net income details
EBT (Quarter) -8.66M14.88M-12.82M-8.80M-10.22M-12.84M-17.14M-15.08M
Tax Provisions (Quarter) 0.03M0.03M0.06M0.11M0.05M0.06M0.06M0.03M
Profit After Tax (Quarter) -8.69M14.85M-12.88M-8.91M-10.27M-12.90M-17.20M-15.11M
Income from Continuing Operations (Quarter) -8.69M14.85M-12.88M-8.91M-10.27M-12.90M-17.20M-15.11M
Consolidated Net Income (Quarter) -8.69M14.85M-12.88M-8.91M-10.27M-12.90M-17.20M-15.11M
Income towards Parent Company (Quarter) -8.69M14.85M-12.88M-8.91M-10.27M-12.90M-17.20M-15.11M
Net Income towards Common Stockholders (Quarter) -8.69M14.85M-12.88M-8.91M-10.27M-12.90M-17.20M-15.11M
Additional items
EPS (Basic) (Quarter) -0.160.27-0.23-0.16-0.19-0.23-0.31-0.27
EPS (Weighted Average and Diluted) (Quarter) -0.160.27-0.23-0.16-0.19-0.23-0.31-0.27
Shares Outstanding (Weighted Average) (Quarter) 55.07M55.10M55.19M55.18M55.21M55.35M55.43M55.52M55.66M
Shares Outstanding (Diluted Average) (Quarter) 55.07M55.10M55.71M55.18M55.21M55.35M55.50M55.52M55.66M
EBITDA (Quarter) -8.92M14.93M-12.31M-9.99M-10.21M-12.67M-17.10M-15.02M
Tax Rate (Quarter) -0.35%0.20%-0.44%-1.20%-0.53%-0.43%-0.36%-0.18%